Asked by: Sureena Brackenridge (Labour - Wolverhampton North East)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will take steps to ensure that the National Cancer Plan for England includes measures that improve (a) early diagnosis and (b) outcomes for people with (i) myeloma and (ii) other blood cancers not covered by staging-based targets.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Early diagnosis is a key focus of the National Cancer Plan. It is a priority for the Government to support the National Health Service to diagnose cancer, including myeloma and other blood cancers, as early and quickly as possible, and to treat it faster, to improve outcomes.
To tackle late diagnoses of blood cancers, the NHS is implementing non-specific symptom pathways for patients who present with symptoms such as weight loss and fatigue, which do not clearly align to a tumour type. Blood cancers are one of the most common cancer types diagnosed through these pathways.
We will get the NHS diagnosing blood cancers earlier and treating them faster, and we will support the NHS to increase capacity to meet the demand for diagnostic services through investment, including for magnetic resonance imaging and computed tomography scanners.
The National Cancer Plan, which will be published in the new year, will include further details on how we will improve outcomes for all cancer patients, including speeding up diagnosis and treatment, ensuring patients have access to the latest treatments and technology, and ultimately driving up this country’s cancer survival rates.
Asked by: Patrick Hurley (Labour - Southport)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of the level of funding allocated by his Department for research and innovation for (a) less survivable and (b) other cancers.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department invests over £1.6 billion each year on research through its research delivery arm, the National Institute for Health and Care Research (NIHR), with cancer as one of its largest areas of spend reflecting its high priority.
An example of this is the NIHR investing £2.4 million into the miONCO-Dx trial, which seeks to develop a blood test designed to detect 12 different cancers, that could transform how cancer is diagnosed in the National Health Service.
The NIHR is also funding a new artificial intelligence (AI) powered radiology analysis service, designed to develop and evaluate the use of AI in medical imaging to improve the detection of cancers. The use of this technology will help to speed up response times and provide more accurate diagnoses and better-targeted treatments, ultimately improving outcomes for patients.
Whist no assessment has been made specifically on the adequacy of the research into less survivable cancers, the NIHR continues to welcome further high-quality proposals from researchers to inform approaches to prevention, treatment, and care in relation to less survivable cancers.
Furthermore, the Department is committed to ensuring that all patients, including those with rare cancers, have access to cutting-edge clinical trials and innovative, lifesaving treatments. The forthcoming National Cancer Plan will include further details on how the NHS will improve diagnosis and outcomes for all cancer patients in England, including for rare and less common cancers.
Asked by: Ian Byrne (Labour - Liverpool West Derby)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether the forthcoming National Cancer Plan for England will include (a) targets to improve the early diagnosis of (i) myeloma and (ii) other blood cancers, and steps to (b) reduce the number of GP visits prior to diagnosis and (c) the proportion of patients diagnosed via emergency departments.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Early diagnosis is a key focus of the National Cancer Plan. It is a priority for the Government to support the National Health Service to diagnose cancer, including blood cancers, as early and quickly as possible, and to treat it faster, to improve outcomes.
To tackle the late diagnoses of blood cancers, the NHS is implementing non-specific symptom pathways for patients who present with symptoms such as weight loss and fatigue, which do not clearly align to a tumour type. Blood cancers are one of the most common cancer types diagnosed through these pathways.
We will get the NHS diagnosing blood cancers earlier and treating them faster, and we will support the NHS to increase capacity to meet the demand for diagnostic services through investment, including for magnetic resonance imaging and computed tomography scanners.
The National Cancer Plan will include further details on how we will improve outcomes for cancer patients, including speeding up diagnosis and treatment, ensuring patients have access to the latest treatments and technology, and driving up this country’s cancer survival rates. The Plan will be published in early 2026.
Asked by: John Hayes (Conservative - South Holland and The Deepings)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help support men to access PSA blood tests on the NHS to check for early warning signs of prostate cancer.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department continues to work with NHS England in the ongoing Help Us Help You Campaigns to raise awareness of prostate cancer and ensure men have access to the information and services they need to make informed decisions about their health.
Men who are concerned about their risk of prostate cancer, or who are experiencing symptoms, are encouraged to discuss prostate specific antigen (PSA) testing with their general practitioner (GP). The National Institute for of Health and Care Excellence has developed guidance for referring patients if prostate cancer is suspected after a physical examination using the suspected cancer referral pathway. The guidance advises clinicians to consider PSA testing only for those with certain symptoms outlined in the guidance.
The Government also published guidance for GP’s on advising men without symptoms of prostate cancer who ask about the PSA test. The guidance advises GPs should use their clinical judgement to manage asymptomatic men and those who they consider to be at increased risk of prostate cancer.
Asked by: Bambos Charalambous (Labour - Southgate and Wood Green)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department plans to increase research funding into new (a) tools and (b) other technologies for the earlier diagnosis of (i) pancreatic, (ii) lung, (iii) liver, (iv) stomach, (v) brain, (vi) oesophageal cancers and (vii) other the less survivable cancers.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department invests over £1.6 billion each year on research through its research delivery arm, the National Institute for Health and Care Research (NIHR).
An example of this is the NIHR investing £2.4 million into the miONCO-Dx trial, which seeks to develop a blood test designed to detect 12 different cancers, that could transform how cancer is diagnosed in the National Health Service.
The NIHR is also funding a new artificial intelligence (AI) powered radiology analysis service, designed to develop and evaluate the use of AI in medical imaging to improve the detection of cancers, including for lung and brain tumours. The use of this technology will help to speed up response times and provide more accurate diagnoses and better-targeted treatments, ultimately improving outcomes for patients.
The NIHR continues to welcome funding applications for research into any aspect of human health and care, including all cancers. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality.
Asked by: Abtisam Mohamed (Labour - Sheffield Central)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking with (a) UK Research and Innovation and (b) the National Institute for Health and Care Research to prioritise further research into early diagnosis of (i) pancreatic cancer and (ii) other less survivable cancers.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department of Health and Social Care invests over £1.6 billion each year on research through its research delivery arm, the National Institute for Health and Care Research (NIHR). Government responsibility for funding cancer research is shared between UK Research and Innovation, funded by the Department for Science, Innovation and Technology and including the Medical Research Council, and the NIHR. Research funders work closely to drive the maximum collective research impact on policy, practice, and individual lives.
NIHR investments are pivotal to informing efforts to improve cancer prevention, treatment, and outcomes. An example of this is the NIHR investing £2.4 million into the miONCO-Dx trial, which seeks to develop a blood test designed to detect 12 different cancers, that could transform how cancer is diagnosed in the National Health Service.
The NIHR continues to welcome funding applications for research into any aspect of human health and care, including all cancers. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality. Welcoming applications on all cancers to all NIHR programmes enables maximum flexibility both in terms of the amount of research funding a particular area can be awarded, and the type of research which can be funded.
The forthcoming National Cancer Plan will include further details on how the NHS will improve diagnosis and outcomes for cancer patients in England.
Asked by: Martin Wrigley (Liberal Democrat - Newton Abbot)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to help improve the diagnosis rate for myeloma cancer in Devon.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
We remain committed to diagnosing all cancer types earlier, including myeloma. To tackle late diagnoses, the National Health Service is implementing non-specific symptom (NSS) pathways for patients who present with symptoms such as weight loss and fatigue, which do not clearly align to a tumour type. Blood cancers are one of the most common cancer types diagnosed through these pathways. There are currently 115 NSS services operating in England, including in Devon, ensuring more patients benefit from quicker access to the right investigations.
We will support the NHS to increase capacity to meet the demand for diagnostic services through investment in new magnetic resonance imaging and computed tomography scanners. The Government is investing an extra £26 billion in the NHS and is opening up community diagnostic centres (CDCs) at evening and weekends, to help diagnose cancer earlier.
We are now delivering additional checks, tests, and scans at 170 CDCs. There are three CDCs located within the NHS Devon Integrated Care Board, all of which deliver services 12 hours a day, seven days a week.
Asked by: Tanmanjeet Singh Dhesi (Labour - Slough)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he plans to include diagnosis targets for myeloma in the national cancer plan for England.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Early diagnosis is a key focus of the National Cancer Plan. It is a priority for the Government to support the National Health Service to diagnose cancer, including blood cancers such as myeloma, as early and quickly as possible, and to treat it faster, to improve outcomes.
To tackle late diagnoses of blood cancers, the NHS is implementing non-specific symptom pathways for patients who present with symptoms such as weight loss and fatigue, which do not clearly align to a tumour type. Blood cancers are one of the most common cancer types diagnosed through these pathways.
We will get the NHS diagnosing blood cancers earlier and treating them faster, and we will support the NHS to increase capacity to meet the demand for diagnostic services through investment, including for magnetic resonance imaging and computed tomography scanners.
The National Cancer Plan will include further details on how we will improve outcomes for cancer patients, including speeding up diagnosis and treatment, ensuring patients have access to the latest treatments and technology, and ultimately driving up this country’s cancer survival rates. Having consulted with key stakeholders and patient groups, the Plan will be published early in the new year.
Asked by: Jim Shannon (Democratic Unionist Party - Strangford)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how much funding his Department has allocated to blood cancers.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department is committed to improving cancer outcomes for patients across England, including for blood cancer.
It is not possible to break down the Department’s overall spend on blood cancer in England as cancer funding is provided across a range of cancer diagnosis and treatment pathways, with national and local cancer initiatives driving improvement across many different cancer types.
Research is crucial in tackling cancer, which is why the Department invests £1.6 billion each year on research through its research delivery arm, the National Institute for Health and Care Research (NIHR), with cancer one of the largest areas of spend. The NIHR made 70 awards for research projects into blood cancer for the period April 2020 to March 2025 with a combined total funding value of approximately £18 million.
Asked by: Tanmanjeet Singh Dhesi (Labour - Slough)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what recent estimate he has made of the average time taken to diagnose myeloma in the South East.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Information on the average time taken to diagnose myeloma in the South East is not held centrally. We publish 28-Day Faster Diagnosis data by suspected cancer, including provider and commissioner data, monthly. The latest publication is available at the following link:
We recognise that there is more to be done to ensure that patients have timely access to diagnosis, and we remain committed to diagnosing all cancer types earlier, including myeloma. To tackle late diagnoses, the National Health Service is implementing non-specific symptom (NSS) pathways for patients who present with symptoms such as weight loss and fatigue, which do not clearly align to a tumour type. Blood cancers are one of the most common cancer types diagnosed through these pathways. There are currently 115 NSS services operating in England, ensuring more patients benefit from quicker access to the right investigations.